New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:23 EDTSRPTSarepta upgraded to Buy from Hold at Needham
Needham upgraded Sarepta due to valuation and continued positive data from the eteplirsen Phase IIb trial. Price target is $36.
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SRPT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use